Ira Wallis
Ph.D.
Partner, VP of Regulatory Affairs
Dr. Wallis brings 20 years of regulatory affairs experience at the vice president, director, and manager level to Pacific BioDevelopment (PBD). Dr. Wallis joined PBD from Tercica, Inc., where he was the Vice President and Head of Regulatory Affairs, and accountable for all regulatory activities. While there, Dr. Wallis was responsible for building the Regulatory Department and overseeing the submission and approval of Tercica’s first drug product, Increlex (mecasermin [DNA origin] injection).
Over a six-year period while at Genentech, Dr. Wallis led the regulatory process and was the principal regulatory contact for FDA/CBER for the approvals of Actimmune (interferon gamma-1b) and Pulmozyme (dornase alfa). Dr. Wallis was a faculty member and postdoctoral fellow at the College of Physicians and Surgeons of Columbia University and holds a Ph.D. in physiology from SUNY Buffalo. His field of research was in Neurobiology (synaptogenesis).
If you need more assistance in determining which of our experienced consultants might best fit your needs, please contact us.
